Research Evidence Comparison# Retatrutide Research# Phase 1 : First-in-human study established safety and pharmacokinetics Phase 2 (n=338) : Published in NEJM (2023), demonstrated dose-dependent weight loss up to 24.2% at 48 weeks with 12 mg dose
Therefore, it will be crucial to direct resources towards primary prevention, early diagnosis, and increased access to treatment [13,14]
This additive effect on energy expenditure is why the retatrutide dosage range studied (112mg weekly) produced weight loss outcomes that exceeded all prior incretin-class compounds in head-to-head timelines
Store in a cool, dry place, away from direct sunlight, and keep the vial tightly closed
Promoting healthy behaviors, such as physical activity and a nutritious diet